🔎 Trials Near Me

Почетна › Рак дојке › Minesota

Kliničke studije za Рак дојке u državi Minesota

64 studija za Рак дојке traži učesnike na lokacijama u državi Minesota.

Gradovi u državi Minesota

Zvanični tekst studije (na engleskom)

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Mayo Clinic - Rochester, Rochester
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • Mercy Hospital, Coon Rapids
  • Minnesota Oncology Hematology PA-Maplewood, Maplewood
  • Abbott-Northwestern Hospital, Minneapolis
  • и још 6
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03418961

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

  • Research Facility, Rochester
Тражи се учесникФаза 1/2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT06590857

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  • Mayo Clinic Cancer Center, Rochester
  • HealthPartners Frauenshuh Cancer Center, Saint Louis Park
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07007559

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  • Metro-Minnesota Community Oncology Research Consortium, Saint Paul
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT03424005

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Minneapolis VA Medical Center, Minneapolis
Тражи се учесникЗдраве особе су добродошле
Узраст од 45 до 75 · Оба пола · Ажурирано 6. 11. 2026. · NCT06995898

Collecting Patient-Reported Experiences With Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy

  • Mayo Clinic in Rochester, Rochester
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06953245

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

  • Mayo Clinic, Rochester
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07214532

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

  • Mayo Clinic, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT05315700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • Minnesota Oncology Hematology, P.A., Minneapolis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  • Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
  • Mayo Clinic in Rochester, Minnesota, Rochester
  • Metro-Minnesota Community Clinical Oncology, Saint Louis Park
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07174336

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • University of Minnesota Medical Center, Minneapolis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06790693

E-Mindfulness Approaches for Living After Breast Cancer

  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Essentia Health Cancer Center, Duluth
  • Mayo Clinic Health Systems-Mankato, Mankato
  • и још 1
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

  • Mayo Clinic in Rochester, Minnesota, Rochester
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Riverwood Healthcare Center, Aitkin
  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Essentia Health - Baxter Clinic, Baxter
  • и још 49
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Minnesota Oncology Hematology, Maplewood
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Minnesota Oncology - Burnsville, Burnsville
  • и још 33
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Mayo Clinic - Rochester, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213791

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Riverwood Healthcare Center, Aitkin
  • Essentia Health - Baxter Clinic, Baxter
  • Sanford Joe Lueken Cancer Center, Bemidji
  • и још 48
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

  • Avera Cancer Institute - Marshall, Marshall
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07405801

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  • Healthpartners Regions Specialty Clinics, Saint Louis Park
  • Healthpartners Regions Specialty Clinics, Saint Paul
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07173751

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Mayo Rochester, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07109726

Avera Cancer Sequencing and Analytics Protocol (ASAP)

  • Avera Cancer Institute - Marshall, Marshall
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT05142033

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

  • Metro Minnesota Community Oncology Consortium (MMCORC), Saint Louis Park
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06401421

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Health Partners Frauenshuh Cancer Center, Saint Louis Park
  • Health Partners Cancer Center at Regions Hospital, Saint Paul
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06172478

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07287917

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  • Minnesota Oncology Hematology, P.A., Burnsville
  • Minnesota Oncology Hematology, P.A., Coon Rapids
  • Minnesota Oncology Hematology, P.A., Edina
  • и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

  • Mayo Clinic, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06374459

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

  • Mayo Clinic Rochester, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07311993

Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities

  • Mayo Clinic in Rochester, Rochester
Тражи се учесник
Узраст 18 и старији · Жене · Ажурирано 5. 10. 2026. · NCT06058650

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • University of Minnesota, Masonic Cancer Center, Minneapolis
  • Mayo Clinic, Rochester
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06369285

Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer

  • Mayo Clinic in Rochester, Rochester
Тражи се учесникФаза 2Здраве особе су добродошле
Узраст од 18 до 45 · Жене · Ажурирано 1. 10. 2026. · NCT05557877

PRE-ISPY Phase I/II Oncology Platform Program

  • University of Minnesota Masonic Cancer Center, Minneapolis
  • Mayo Clinic Comprehensive Cancer Center, Rochester
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT05868226

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

  • Mayo Clinic, Rochester
Тражи се учесник
Узраст 30 и старији · Жене · Ажурирано 25. 9. 2026. · NCT02945579

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  • Research Site, Saint Paul
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06103864

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  • Clinical Trial Site, Minneapolis
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07085767

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

  • Mayo Clinic, Rochester
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT07340541

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

  • University of Minnesota Masonic Cancer Center, Minneapolis
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT07216105

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Rochester
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06072612

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

  • Mayo Clinic, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06488378

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.